Beyond Injections: A Deep Dive into the Robust Clinical Pipeline of Dry AMD Therapies, from Oral RBP4 Inhibitors to Groundbreaking Gene and Stem Cell Replacement Strategies
The development pipeline for the Dry Age Related Macular Degenera-tion Amd Market is unprecedentedly rich, reflecting the massive potential return on investment for an effective therapy. Researchers are exploring diverse mechanisms of action beyond complement inhibition, with a strong focus on addressing the root causes of retinal cell death and dysfunction. Key emerging therapeutic classes...
0 Comments 0 Shares 581 Views 0 Reviews